Exhibit 99.1 • Advancement of SER-270 for Tardive Dyskinesia: In July 2025, Serina announced the advancement of SER-270 (POZ- VMAT2i), a once-weekly injectable therapy for tardive dyskinesia (TD), enabled by the POZ Platform. The program aims to address unment needs in TD treatment, particularly for institutional use and adherence challenges. SER-270 may also be evaluated for Huntington's disease chorea, a high need indication with limited long-acting injectable (LAI) options. • Board Appointments: In May 2 ...